These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 25348907)
21. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Alford JC; Saseen JJ; Allen RR; Nair KV Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173 [TBL] [Abstract][Full Text] [Related]
22. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. Karimi S; Hough A; Beckey C; Parra D J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676 [TBL] [Abstract][Full Text] [Related]
23. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing. Prom R; Umscheid CA; Kasbekar N; Spinler SA Am J Health Syst Pharm; 2013 Nov; 70(21):1878-9. PubMed ID: 24128959 [No Abstract] [Full Text] [Related]
24. Impact of pharmacists' interventions and simvastatin dose restrictions. Shoulders BR; Franks AS; Barlow PB; Williams JD; Farland MZ Ann Pharmacother; 2014 Jan; 48(1):54-61. PubMed ID: 24259645 [TBL] [Abstract][Full Text] [Related]
25. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911 [TBL] [Abstract][Full Text] [Related]
26. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Tuchscherer RM; Nair K; Ghushchyan V; Saseen JJ Am J Cardiovasc Drugs; 2015 Feb; 15(1):27-34. PubMed ID: 25348907 [TBL] [Abstract][Full Text] [Related]
27. Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm. Finks SW; Campbell JD Nurse Pract; 2014 Nov; 39(11):45-51. PubMed ID: 25325525 [TBL] [Abstract][Full Text] [Related]
29. Does simvastatin cause more myotoxicity compared with other statins? Backes JM; Howard PA; Ruisinger JF; Moriarty PM Ann Pharmacother; 2009 Dec; 43(12):2012-20. PubMed ID: 19920157 [TBL] [Abstract][Full Text] [Related]
30. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Devabhaktuni M; Bangalore S Vasc Health Risk Manag; 2009; 5(1):377-87. PubMed ID: 19475775 [TBL] [Abstract][Full Text] [Related]
31. New simvastatin dosing recommendations. Med Lett Drugs Ther; 2011 Aug; 53(1370):61-2. PubMed ID: 21836544 [No Abstract] [Full Text] [Related]
32. Safety considerations with fenofibrate/simvastatin combination. Filippatos TD; Elisaf MS Expert Opin Drug Saf; 2015; 14(9):1481-93. PubMed ID: 26134595 [TBL] [Abstract][Full Text] [Related]
33. Simvastatin interactions with other drugs. Florentin M; Elisaf MS Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996 [TBL] [Abstract][Full Text] [Related]
34. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Filippatos TD; Elisaf MS Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529 [TBL] [Abstract][Full Text] [Related]
35. Atorvastatin calcium plus amlodipine for the treatment of hypertension. Delgado-Montero A; Zamorano JL Expert Opin Pharmacother; 2012 Dec; 13(18):2673-85. PubMed ID: 23140185 [TBL] [Abstract][Full Text] [Related]
36. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999 [TBL] [Abstract][Full Text] [Related]
37. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Frampton JE; Scott LJ Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840 [TBL] [Abstract][Full Text] [Related]